INTRODUCTION
============

Besides cognitive impairment, Alzheimer\'s disease (AD) is often accompanied by various neuropsychiatric symptoms in both early and late stages.[@B1] For instance, up to 88% of AD patients suffer from one or more neuropsychiatric symptoms over the course of the disease.[@B2] These symptoms can complicate the course of AD and adversely affect quality of life of both patients and caregivers.[@B3]

Apathy characterized by reduced motivation, decreased initiative and interest, and blunting of emotions[@B4] is one of the most frequent neuropsychiatric symptoms in AD patients.[@B2] Apathy in AD is related to faster cognitive deterioration, reduced daily functioning, early institutionalization, increased mortality risk, higher caregiver distress, and increased economic burden.[@B5] In addition, apathy is a major barrier to the management of AD patients since they may receive less benefit from non-pharmacological therapies.[@B6]

Previous neuroimaging studies have identified neurobiological correlates of apathy in AD during the past decades. Among various imaging modalities, single-photon emission computed tomography (SPECT) has been used extensively to examine brain perfusion. Although hypoperfusion in prefrontal-subcortical regions including the anterior cingulate and orbitofrontal cortices in AD patients with apathy has been suggested,[@B7] this remains controversial. Moreover, most studies were performed with relatively limited number of patients.[@B7]

The objective of the present study was to investigate differences in regional cerebral blood flow (rCBF) between AD patients with apathy and those without apathy using perfusion SPECT. Furthermore, correlation between rCBF and levels of apathy in apathetic AD patients was examined.

METHODS
=======

Participants
------------

Patients with AD were recruited from Incheon St. Mary\'s Hospital (Incheon, South Korea). The diagnosis for probable AD was made based on the Diagnostic and Statistical Manual of Mental Disorders-IV[@B8] and the National Institute of Neurological and Communicative Disorders and Stroke-AD Related Disorders Association criteria.[@B9] AD patients who scored 0 on apathy item of the Neuropsychiatric Inventory (NPI)[@B10] were assigned to "AD without apathy" group while those who scored 1 or above on apathy item were assigned to "AD with apathy" group. Patients with history of head trauma, stroke, epilepsy, mixed or vascular dementia, other neurological or psychiatric disorders were excluded from this study. This study was approved by the Institutional Review Board of Incheon St. Mary\'s Hospital (OC11OISI0098), and all participants provided written informed consent.

Clinical assessment
-------------------

Neurologists conducted clinical examinations including medical history and physical assessment. Cognitive performance and neuropsychiatric symptoms were evaluated with Mini-Mental State Examination (MMSE)[@B11] and NPI,[@B10] respectively. Global severity of dementia was assessed with Clinical Dementia Rating (CDR)[@B12] and CDR-Sum of Boxes (CDR-SOB).

SPECT image acquisition
-----------------------

Brain perfusion SPECT images were acquired using a dual-headed rotating gamma camera (Discovery NM630, GE Healthcare, Milwaukee, WI, USA) equipped with a low-energy fan-beam collimator. Patients were administered intravenously with 555 MBq of technetium-99m hexamethylpropylene amine oxime approximately 20 minutes before scanning. Patients were in supine resting state with their eyes open during the scan. Images were taken at a rate of 12 seconds per frame by rotating the camera a total of 720° at 6-degree intervals. Continuous transaxial images were reconstructed using the standard ordered subset expectation maximization (OSEM 6 iterations, 10 subsets) algorithm with a Butterworth filter (cutoff frequency of 0.5 cycles/pixel, power 10) to reduce noise. Matrix size, pixel size, field of view, slice thickness, and energy windows of reconstructed images were 128×128, 1.95 mm×1.95 mm, 250 mm, 2.08 mm, and 140 keV±20%, respectively. Chang\'s attenuation correction method was used for correction of tissue attenuation.[@B13]

SPECT image analysis
--------------------

Statistical Parametric Mapping 12 (SPM; Wellcome Department of Cognitive Neurology, Institute of Neurology, London, UK) was used for image analysis. All SPECT images were spatially normalized to SPM SPECT template (Montreal Neurological Institute, McGill University, Montreal, Canada) and resliced with a voxel size of 2 mm×2 mm×2 mm. Images were then smoothed with an isotropic Gaussian kernel (12 mm full-width at half-maximum). Voxel intensities were scaled to the mean intensity of the cerebellum using Automated Anatomical Labeling atlas.[@B14][@B15][@B16] Global counts were normalized using proportional scaling to a mean value of 50 mL/100 g/min. Group differences in rCBF were assessed using analysis of covariance with age, sex, and MMSE score as covariates. Height threshold was set at *p*\<0.005 while extent threshold was 100 or more contiguous voxels.

Statistical analysis
--------------------

Independent *t*-test and χ^2^ test were used for comparisons of continuous and categorical variables between the 2 groups, respectively. In AD with apathy group, linear regression was performed to examine the association between mean perfusion across all significant clusters and NPI apathy score. All statistical analyses were conducted with Stata version 13.1 (StataCorp., College Station, TX, USA). A 2-tailed *p*\<0.05 was considered statistically significant.

RESULTS
=======

Demographic and clinical characteristics
----------------------------------------

A total of 66 apathetic AD patients and 66 AD patients without apathy were included in the analysis. Demographic and clinical characteristics of these patients are summarized in [Table 1](#T1){ref-type="table"}. Age (*t*=−0.09; *p*=0.92), sex (χ^2^=1.84; *p*=0.18), or education (*t*=0.40; *p*=0.69) did not differ between the 2 groups. There were no significant differences in scores of MMSE (*t*=0.28; *p*=0.78), CDR (χ^2^=0.33; *p*=0.57), or CDR-SOB (*t*=0.68; *p*=0.50) between the 2 groups. NPI scores except apathy score (*t*=11.28; *p*\<0.001) did not differ between the 2 groups either.

###### Demographic and clinical characteristics of participants

![](dnd-17-50-i001)

  Characteristics           AD with apathy (*n*=66)   AD without apathy (*n*=66)   Statistics            
  ------------------------- ------------------------- ---------------------------- --------------------- -----------------------
  Age (yr)                  76.1±7.2                  76.2±9.2                     *t*=−0.09; *p*=0.92   
  Sex (male/female)         22/44                     15/51                        χ^2^=1.84; *p*=0.18   
  Years of education (yr)   5.9±4.5                   5.6±4.3                      *t*=0.40; *p*=0.69    
  MMSE                      19.0±4.6                  18.8±4.6                     *t*=0.28; *p*=0.78    
  CDR                                                                              χ^2^=0.33; *p*=0.57   
                            0.5                       48                           45                    
                            1                         18                           21                    
  CDR-SOB                   3.3±1.9                   3.1±2.0                      *t*=0.68; *p*=0.50    
  NPI                                                                                                    
                            Delusions                 0.6±1.7                      0.9±2.3               *t*=−0.64; *p*=0.52
                            Hallucinations            0.4±1.3                      0.6±2.0               *t*=−0.63; *p*=0.53
                            Agitation                 0.9±1.4                      1.1±2.2               *t*=−0.75; *p*=0.45
                            Depression                1.6±2.4                      1.1±1.7               *t*=1.33; *p*=0.18
                            Anxiety                   1.3±2.1                      1.0±1.9               *t*=0.81; *p*=0.42
                            Elation                   0.2±0.8                      0.1±0.5               *t*=1.05; *p*=0.30
                            Apathy                    4.3±3.1                      0.0±0.0               *t*=11.28; *p*\<0.001
                            Disinhibition             0.6±1.6                      0.5±1.2               *t*=0.12; *p*=0.90
                            Irritability              1.8±2.4                      1.4±2.1               *t*=1.00; *p*=0.32
                            Aberrant motor behavior   1.3±2.9                      1.7±3.6               *t*=−0.66; *p*=0.51
                            Sleep disorders           1.8±3.0                      1.5±2.9               *t*=0.65; *p*=0.51
                            Eating disorders          2.2±3.0                      1.4±2.5               *t*=1.51; *p*=0.13

AD: Alzheimer\'s disease, MMSE: Mini-Mental State Examination, CDR: Clinical Dementia Rating, CDR-SOB: Clinical Dementia Rating-Sum of Boxes, NPI: Neuropsychiatric Inventory.

Differences in brain perfusion
------------------------------

AD patients with apathy showed lower rCBF in the bilateral orbitofrontal cortex, left putamen, left nucleus accumbens, left thalamus, and bilateral insula (all *p*\<0.005) than those without apathy ([Table 2](#T2){ref-type="table"} and [Fig. 1](#F1){ref-type="fig"}). However, higher rCBF was not found in AD with apathy group. The mean perfusion across all significant clusters showed a negative correlation with NPI apathy score in AD patients with apathy (β=−0.25; *p*=0.04).

###### Differences in regional cerebral blood flow between AD patients with apathy and those without apathy

![](dnd-17-50-i002)

  Regions                               *t*                                                            *p*    Coordinates^\*^ (x, y, z)   Cluster size (voxels)   
  ------------------------------------- -------------------------------------------------------------- ------ --------------------------- ----------------------- -----
  AD with apathy \> AD without apathy                                                                                                                             
                                        None                                                                                                                      
  AD with apathy \< AD without apathy                                                                                                                             
                                        L orbitofrontal cortex, putamen, nucleus accumbens, thalamus   3.47   \<0.001                     −6, 0, −10              557
                                        R insula                                                       3.31   0.001                       44, 4, 2                334
                                        L orbitofrontal cortex                                         3.27   0.001                       −48, 26, −10            179
                                        L insula                                                       3.07   0.001                       −42, 4, 4               102
                                        R frontal pole, orbitofrontal cortex                           2.92   0.002                       46, 40, −12             121

AD: Alzheimer\'s disease, L: left, R: right.

^\*^The coordinates refer to the Montreal Neurological Institute coordinate system.

![Differences in regional cerebral blood flow between AD patients with apathy and those without apathy. At each voxel, decreases in brain perfusion in AD patients with apathy appear in blue-green. The height threshold is set at *p*\<0.005 and extent threshold is 100 or more contiguous voxels. Images are shown in neurological convention. Color bar represents voxel-level *t*-values.\
AD: Alzheimer\'s disease.](dnd-17-50-g001){#F1}

DISCUSSION
==========

In the present study, we investigated differences in rCBF between AD patients with apathy and those without apathy using brain perfusion SPECT. AD patients with apathy demonstrated lower cerebral perfusion in the orbitofrontal cortex, putamen, nucleus accumbens, thalamus, and insula compared to those without apathy. Moreover, reduced rCBF in those areas was linearly associated with more severe apathy. These results suggest that hypoperfusion in the prefrontal, striatal, and insular regions may be implicated in the pathophysiology of apathy in AD patients.

Previous studies have consistently reported hypoperfusion, hypometabolism, and atrophy of the orbitofrontal cortex in AD patients with apathy.[@B7] The orbitofrontal cortex is a part of the prefrontal-striatal network. It evaluates action and reward by integrating sensory, affective, and motivational information.[@B17] Specifically, this area recognizes salient stimuli and modulates responses to these stimuli based on one\'s motivation. Dysfunction of the orbitofrontal cortex may lead to impairment of decision-making and response inhibition that are characteristics of apathy.[@B7]

In this study, AD patients with apathy were found to have lower rCBF in the putamen, nucleus accumbens, and thalamus than those without apathy, similar to results of previous studies showing hypoperfusion of the basal ganglia[@B18] and hypometabolism of the thalamus[@B19] in apathetic AD patients. Other studies have suggested that gray matter volume losses in the putamen and nucleus accumbens are correlated with apathy in patients with AD[@B20] and Parkinson\'s disease (PD),[@B21] respectively. The prefrontal-striatal network is organized as feed-forward loop from the prefrontal cortex to the striatum which in turn projects to the thalamus and backs to the prefrontal region. This network is important for goal-directed behavior and executive function. Damage to this circuit may lead to apathy through cognitive, emotional, and motivational impairments.[@B22] For instance, striatal dopamine transporter levels are negatively associated with apathy in patients with AD or dementia with Lewy body.[@B23] The commonest behavioral symptom in patients with basal ganglia lesions is also apathy.[@B24] Furthermore, dysfunction of the prefrontal-striatal network has been implicated in apathy among patients with other neuropsychiatric disorders including frontotemporal dementia, schizophrenia, and mood disorders.[@B25]

Associations between the insula and apathy have been reported in previous studies on various neurodegenerative disorders. Apathy is related to atrophy of the insula in AD and progressive supranuclear palsy[@B26] as well as PD.[@B27] Patients with PD also show apathy-related hypometabolism in the insula.[@B28] In healthy volunteers, insula activation during volitional behavior tasks has been observed.[@B29] The insula is closely involved not only in high-level cognitive control, attentional processes, and regulation of emotion and behavior, but also in metacognitive process of self-awareness by integrating external sensory stimuli with internal states.[@B30] Although the exact role of the insula in apathetic patients remains unclear, dysfunction of the insula may lead to impaired insight and self-awareness which in turn may result in apathy.[@B31]

Potential limitations of this study are as follows. First, the cross-sectional design of the present study does not permit causal inferences. Further longitudinal studies are warranted to disentangle pre-existing vulnerabilities and acquired deficits. Second, the definition of apathy depends on specific assessment tools used. Thus, generalization across other evaluation methods could be important. Third, psychotropic medication was not considered in this study. It might influence the results.

In conclusion, the results of this study demonstrated that hypoperfusion in the prefrontal, striatal, and insular areas was associated with apathy in AD patients, controlling for demographic characteristics, cognitive performance, and other neuropsychiatric symptoms. The findings of this study suggest that dysfunction in these regions may be underlying neural correlates of apathy in AD patients.
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